Market revenue in 2023 | USD 627.4 million |
Market revenue in 2030 | USD 1,874.1 million |
Growth rate | 16.9% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Service |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Service |
Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to crispr and cas genes market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 78.58% in 2023. Horizon Databook has segmented the Europe crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Europe's CRISPR and Cas genes market is affected by multiple factors, both positive and negative. In July 2019, a European court ruling has imposed strict regulations on gene-edited crops that have created issues for food testing laboratories across Europe.
In January 2020, the European Patent Office (EPO) revoked the patent for CRISPR-Cas technology provided by the Broad Institute of the U.S., due to lack of entitlement. Despite the presence of strict regulations, this region has witnessed rapid adoption of CRISPR for biomedical, therapeutic, and drug delivery applications.
The 3rd International Conference on CRISPR Technologies, held in Germany and presented by the Society for Biological Engineering, is anticipated to increase awareness and encourage the adoption of CRISPR and Cas genes. The conference highlighted developments and challenges of CRISPR technologies.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe crispr and cas genes market , including forecasts for subscribers. This continent databook contains high-level insights into Europe crispr and cas genes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account